Neuro-Oncology Reviews
Volume
26 Number 1
15 January 2024
Home > Publications > Neuro-Oncology Reviews > Volume 26, Year 2024 > Number 1, 15 January
Albert NL, Galldiks N, Ellingson
BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law
I, Le Rhun E, Mair MJ, Minniti G, Rudà R, Scott AM, Short
SC, Smits M, Suchorska B, Tolboom N, Traub-Weidinger T, Tonn JC,
Verger A, Weller M, Wen PY, Preusser M.
PET-based
response assessment criteria for diffuse gliomas (PET RANO 1.0): a
report of the RANO group.
Lancet
Oncol. 2024 Jan
2;25(1):e29-e41. doi:
10.1016/S1470-2045(23)00525-9. PMID:
38181810. Review, Guidelines˰ ˍ
Tosi U, Souweidane M.
Diffuse
Midline Gliomas: Challenges and New Strategies in a Changing
Clinical Landscape.
Cancers
(Basel). 2024 Jan 2;16(1):219. doi:
10.3390/cancers16010219. PMID:
38201646. Review. ˍ
Vermeulen E, Vander Mijnsbrugge AS,
Brock S, Vaeyens F, Dirven I, Ciçek A, Marcelis W, Klein S,
Bruneau M, Neyns B, Duerinck J.
Successful
Treatment with Dabrafenib/Trametinib of a Malignantly Transformed
and Metastasized BRAF V600E Mutant Pleiomorphic Xanthoastrocytoma:
A Case Report and Review of the Literature.
Case
Rep Oncol. 2024
Jan 3;17(1):10-16. doi:
10.1159/000534731. PMID:
38179547. Case report, Review. ˍ
Youssef G, Wen PY.
Updated
Response Assessment in Neuro-Oncology (RANO) for Gliomas.
Curr
Neurol Neurosci Rep.
2024 Jan 3. doi:
10.1007/s11910-023-01329-4. PMID:
38170429. Review˰ ˍ
Besbris JM, Taylor LP.
Palliative
Care in Neuro-Oncology.
Semin
Neurol. 2024 Jan
4. doi:
10.1055/s-0043-1777703. PMID:
38176423. Review˰ ˍ
Bonm AV, Taylor LP.
Management
of Neurologic Complications in Patients with Brain and Spine
Tumors.
Semin
Neurol. 2024 Jan
4. doi:
10.1055/s-0043-1777422. PMID:
38176424. Review˰ ˍ
Pinkiewicz M, Pinkiewicz M, Walecki
J, Zaczyński A, Zawadzki M.
Breaking
Barriers in Neuro-Oncology: A Scoping Literature Review on
Invasive and Non-Invasive Techniques for Blood-Brain Barrier
Disruption.
Cancers
(Basel). 2024 Jan 4;16(1):236. doi:
10.3390/cancers16010236. PMID:
38201663. Review. ˍ
Buccilli
B, Rodriguez Molina MA, Redrovan Palomeque DP, Herrera Sabán
CA, Caliwag FMC, Contreras Flores CJS, Abeysiriwardana CWJ, Diarte
E, Arruarana VS, Calderon
Martinez E.
Liquid
Biopsies for Monitoring Medulloblastoma: Circulating
Tumor
DNA as a Biomarker for Disease Progression and Treatment
Response.
Cureus.
2024
Jan 5;16(1):e51712. doi:
10.7759/cureus.51712. PMID:
38313884. Review. ˍ
Dong C, Yu X, Jin K, Qian
J.
Overcoming
brain barriers through surface-functionalized liposomes for
glioblastoma therapy; current status, challenges and future
perspective.
Nanomedicine
(Lond). 2024 Jan 5. doi:
10.2217/nnm-2023-0172. PMID:
38180008. Review˰ ˍ
Stitzlein LM, Adams JT, Stitzlein
EN, Dudley RW, Chandra J.
Current
and future therapeutic strategies for high-grade gliomas
leveraging the interplay between epigenetic regulators and kinase
signaling networks.
J
Exp Clin Cancer Res.
2024 Jan 5;43(1):12. doi:
10.1186/s13046-023-02923-7. PMID:
38183103. Review. ˍ
*Xiong Z, Raphael I, Olin M, Okada
H, Li X, Kohanbash G.
Glioblastoma
vaccines: past, present, and opportunities.
EBioMedicine.
2024 Jan 5;100:104963. doi:
10.1016/j.ebiom.2023.104963. PMID:
38183840. Review. ˍ
Cuneo A, Murinova N.
Headache
Management in Individuals with Brain Tumor.
Semin
Neurol. 2024 Jan
6. doi:
10.1055/s-0043-1777423. PMID:
38183973. Review. ˍ
McGranahan TM, Figuracion KC,
Goldberg M, Sheppard DP.
Neurologic
Complications in Adult Cancer Survivorship.
Semin
Neurol. 2024 Jan
6. doi:
10.1055/s-0043-1777424. PMID:
38183974. Review˰ ˍ
Ding X, Liang T, Liang B, Zhou X, Chen J, Gao H, Wang F, Zheng X,
Feng E.
Clinical characteristics and
prognostic analysis of patients with HIV and glioma: A case series
and literature review.
Exp
Ther Med. 2024 Jan 8;27(2):90. doi:
10.3892/etm.2024.12380. PMID:
38274346. Case report, Review. ˍ
Guterres A, Filho PNS, Moura-Neto
V.
Breaking
Barriers: A Future Perspective on Glioblastoma Therapy with
mRNA-Based Immunotherapies and Oncolytic Viruses.
Vaccines
(Basel). 2024 Jan 8;12(1):61. doi:
10.3390/vaccines12010061. PMID:
38250874. Perspective. ˍ
Santorsola M, Caraglia M, Ottaiano
A.
Editorial:
Type 2 diabetes and cancer: clinical and molecular
interactions.
Front
Med (Lausanne).
2024 Jan 8;10:1345732. doi:
10.3389/fmed.2023.1345732. PMID:
38259859. Editorial. ˍ
Zhang H, Chen Y, Jiang X, Gu Q, Yao J, Wang X, Wu J.
Unveiling
the landscape of cytokine research in glioma immunotherapy: a
scientometrics analysis.
Front
Pharmacol. 2024 Jan 8;14:1333124. doi:
10.3389/fphar.2023.1333124. PMID:
38259287. Bibliometric analysis. ˍ
Kinslow CJ, Garton ALA, Rae AI,
Kocakavuk E, McKhann GM, Cheng SK, Sisti MB, Bruce JN, Wang
TJC.
Extent
of resection for low-grade gliomas - Prognostic or
therapeutic?
Clin
Neurol Neurosurg.
2024 Jan 9;236:108117. doi:
10.1016/j.clineuro.2024.108117. PMID:
38219356. Editorial˰ ˍ
Yu P, Wang Y, Su F, Chen
Y.
Comparing
[18F]FET PET and [18F]FDOPA PET for glioma recurrence diagnosis: a
systematic review and meta-analysis.
Front
Oncol. 2024 Jan
10;13:1346951. doi:
10.3389/fonc.2023.1346951. PMID:
38269019. Review, Meta-analysis. ˍ
Dagher R, Gad M, da Silva de
Santana P, Sadeghi MA, Yewedalsew SF, Gujar SK, Yedavalli V,
Köhler CA, Khan M, Tavora DGF, Kamson DO, Sair HI, Luna
LP.
Umbrella
review and network meta-analysis of diagnostic imaging test
accuracy studies in Differentiating between brain tumor
progression versus pseudoprogression and radionecrosis.
J
Neurooncol. 2024
Jan 11. doi:
10.1007/s11060-023-04528-8. PMID:
38212574. Review, Meta-analysis˰ ˍ
Shikalov A, Koman I, Kogan NM.
Targeted
Glioma Therapy-Clinical Trials and Future
Directions.
Pharmaceutics.
2024 Jan 11;16(1):100. doi:
10.3390/pharmaceutics16010100. PMID:
38258110. Review. ˍ
Cho S, Chu MK.
Headache in Brain
Tumors.
Neurol
Clin. 2024 Jan 12;42(2):487-496. doi:
10.1016/j.ncl.2023.12.004. PMID:
38575261. Review˰ ˍ
Zheng X, Yang J, Hou Y, Shi X, Liu K.
Prediction
of clinical progression in nervous system diseases: plasma glial
fibrillary acidic protein (GFAP).
Eur
J Med Res. 2024 Jan 12;29(1):51. doi:
10.1186/s40001-023-01631-4. PMID:
38216970. Review. ˍ
*Zhou Y, Liu M, Huang X, Liu Z, Sun
Y, Wang M, Huang T, Wang X, Chen L, Jiang X.
Emerging
trends and thematic evolution of immunotherapy for glioma based on
the top 100 cited articles.
Front
Oncol. 2024 Jan
12;13:1307924. doi:
10.3389/fonc.2023.1307924. PMID:
38293697. Bibliometric analysis. ˍ
Wang
H, Yang J, Li X, Zhao H.
Current
state of immune checkpoints therapy for
glioblastoma.
Heliyon.
2024 Jan 13;10(2):e24729. doi:
10.1016/j.heliyon.2024.e24729.
PMID:
38298707. Review. ˍ
Palavani LB, de Barros Oliveira L, Reis PA, Batista S, Santana LS,
de Freitas Martins LP, Rabelo NN, Bertani R, Welling LC,
Figueiredo EG, Paiva WS, Neville IS.
Efficacy
and Safety of Intraoperative Radiotherapy for High-Grade Gliomas:
A Systematic Review and Meta-Analysis.
Neurosurg
Rev. 2024 Jan 15;47(1):47. doi:
10.1007/s10143-024-02279-2. PMID:
38221545. Review, Meta-analysis˰
ˍ
Topics